Leveraging proven technology from Eurogentec, AnaSpec's parent company, this protocol uses a proprietary mixture of Freund's free immuno-stimulatory compounds.
Two new mouse monoclonal antibodies specific for β-Amyloid (1-40) & (1-42) are of the IgG1 subtype and do not cross-react with each other at concentrations up to 50 ng/ml when tested in sandwich ELISA.
ISO 17025-accredited Beta Analytic, Inc., will participate in the 1st World Congress of Bioenergy (WCBE-2011) to be held at the World Expo Center in Dalian, China, from April 25 to April 30, 2011. Research & Development Associate Pat Patodia and China Operations Manager Fuming "Steven" Liu are representing Beta Analytic at the event.
The relaunch of GXP Engaged Auditing Services as an independent company enables it to work with those companies such as CROs, pharmaceutical, biotechnology, medical device or public companies or regulatory or QM service providers, who could not or would not work with the company before.
Gateway Analytical will present a workshop titled, "Raman Chemical Imaging for In Vitro Particle Characterization in Inhalables," on May 4 at Respiratory Drug Delivery Europe 2011 in Berlin, Germany.
Concerns are frequently raised in the pharmaceutical industry over the danger that when clinical trials are outsourced to contact research organisations (CROs), ethical protections might take a backseat to quicker and cheaper new product development.
AnaSpec, Eurogentec Group is pleased to be the first in the industry to establish a new product line of zebrafish specific (Z-Fish™) antibodies to support the increasing needs of researchers.
You are invited to attend Dr. Goburru's webinar The "Learn & Apply" Paradigm in Drug Development on April 18, 2011 at 1:00 pm EST (GMT -5:00) (www.rosaandco.com/webinar). This talk will summarize the state of the art in applying drug-disease-trial modeling to decision-making processes in drug development.
Gateway Analytical will be exhibiting its materials characterization and industrial problem-solving services at booth number 431 at the Materials Research Society Spring Meeting and Exhibit, April 25-29, Moscone West Convention Center, San Francisco.
PBI releases SimLipid, a comprehensive lipid identification tool, supporting lipid MS/MS data analysis and correction of peak intensities for MS lipid profiles with overlapping isotopes.
Ray Miller, Global Business Development Manager in Biomaterials and Specialties, at DuPont Applied BioSciences, will give a presentation at GTC's 2nd Annual Biobased Chemicals - Inception to Market Conference on July 7-8, 2011 in San Francisco, CA.
Signaling an aggressive escalation of his campaign to promote his status as the creator of the first functioning prototype of warp drive, research and development engineer Marshall Barnes announces the imminent release of a "defining work" on the real physics of warp drive.
Aquatic Informatics has been named to the "Ready to Rocket" list for the last four years based on its consistent growth and high potential to accelerate that growth in 2011.
Onyx Scientific excel in streamlining GMP-approved processes and difficult-to-synthesise APIs. Their compliance standards minimise impurities, reduce costs and significantly improve timelines for phase I and II clinical studies.
Enertia Engineering Ltd., a leading electrical equipment company, is pleased to announce, after 2 years of research, development, and commercialization, the EnerPulsar Anti-Islanding protection system is now commercially available in North America.
With two thirds of all clinical trials being outsourced and inefficiencies leading to 70% of all trials failing to complete on time; establishing CRO accountability, running trials in emerging markets and entering into risk sharing partnerships are discussed as possible solutions.
Particle size advancements in nasal spray suspensions using Raman chemical imaging will be presented by scientists at Gateway Analytical at the Pittcon Conference and Expo 2011.
Susan Schneider, Director, Discovery Medicine, GSK Ophthalmology will give a featured presentation at GTC's 3rd Ocular Disease Drug & Discovery Conference, May 26- 27, 2011 in Boston, MA.
Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio's 3rd Ocular Disease & Drug Discovery Conference, May 26-27, 2011 in Boston, MA.
William C. Shakespeare, Ph.D., Vice President, Drug Discovery at ARIAD Pharmaceuticals to give featured presentation on "Tackling Mutation-Based Resistance in Kinase Drug Discovery: Ponatinib, a Pan-BCR-ABL Inhibitor and AP26113, A Next Generation ALK Inhibitor" at GTCbio's 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA.
Satisfied Users & 
Approved Press Releases
